Moody Lynn & Lieberson LLC lessened its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 59.8% during the 1st quarter, Holdings Channel reports. The fund owned 1,087 shares of the medical instruments supplier’s stock after selling 1,616 shares during the quarter. Moody Lynn & Lieberson LLC’s holdings in Becton Dickinson and were worth $271,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of the company. IMS Capital Management purchased a new position in shares of Becton Dickinson and during the 3rd quarter valued at $29,000. RPG Investment Advisory LLC bought a new stake in shares of Becton Dickinson and in the 1st quarter worth about $32,000. Nalls Sherbakoff Group LLC bought a new stake in shares of Becton Dickinson and in the 4th quarter worth about $34,000. Aspire Private Capital LLC bought a new stake in shares of Becton Dickinson and in the 4th quarter worth about $39,000. Finally, Sontag Advisory LLC bought a new stake in shares of Becton Dickinson and in the 4th quarter worth about $43,000. Institutional investors and hedge funds own 84.87% of the company’s stock.
In other news, CEO Vincent A. Forlenza sold 3,123 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $255.03, for a total value of $796,458.69. Following the completion of the sale, the chief executive officer now owns 215,372 shares of the company’s stock, valued at approximately $54,926,321.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ribo Alberto Mas sold 4,808 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $255.03, for a total transaction of $1,226,184.24. Following the completion of the sale, the executive vice president now directly owns 22,476 shares of the company’s stock, valued at approximately $5,732,054.28. The disclosure for this sale can be found here. Insiders sold a total of 29,684 shares of company stock valued at $7,518,574 in the last ninety days. Corporate insiders own 0.12% of the company’s stock.
Becton Dickinson and stock opened at $228.04 on Wednesday. The stock has a market capitalization of $61.32 billion, a price-to-earnings ratio of 20.71, a P/E/G ratio of 1.57 and a beta of 1.21. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.97 and a quick ratio of 0.62. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.58 by $0.12. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The firm had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the prior year, the company earned $2.48 EPS. The company’s revenue was up 35.1% compared to the same quarter last year. As a group, research analysts expect that Becton Dickinson and Co will post 12.08 earnings per share for the current fiscal year.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Leveraged Buyout (LBO) Explained
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.